Pre-Clinical Activity Of Combined LSD1 And Mtorc1 Inhibition In MLL-Translocated Acute Myeloid Leukaemia

30 Jun, 2020 ,

Gauri Deb conducted a study to identify genes and cellular pathways that collaborate with LSD1 to maintain the leukaemic phenotype, and which could be targeted by combination therapies, the researchers performed a genome-wide CRISPR-Cas9 dropout screen. They concluded that dual mTORC1 and LSD1 inhibition represents a candidate combination approach for enhanced differentiation in MLL-translocated AML which could be evaluated in early phase clinical trials.